Tragic Triad of Tobacco Dependence, Cancer, and COVID-19 Pandemic: An Urgent Call for Attention by Health Care Systems and Professionals

Tobacco smoke is a well-known carcinogen associated with multiple malignancies. Patients with cancer, as well as survivors, who continue to smoke are at a greater risk for poor cancer treatment outcomes. With the emergence of the COVID-19 pandemic, there is increased frequency and severity of the infection in patients with cancer. Furthermore, smoking and/or vaping increases incidence or likelihood of progression of COVID-19. Cigarette smoking, cancer, and COVID-19 each impose disproportionate burden of illness and death among racial and ethnic minorities. Geographic and population-specific analyses reveal that neighborhoods with lower income and higher minority populations have more tobacco/vape shops and face increased risk associated with tobacco marketing. Referral to tobacco cessation has been reduced during the pandemic. To reduce the adverse health effects of tobacco dependence among patients with cancer during the pandemic, urgent evidence-based solutions are described for health systems and professionals to prioritize tobacco cessation for patients with cancer in the midst of the COVID-19 pandemic, on the basis of cessation implementation at City of Hope Medical Center.

Tobacco use and Dependence in Adolescents: A Review

Despite rising acknowledgement of the onset of tobacco smoking in children and adolescents, foundational understanding about many elements of early-life smoking behavior, as well as statistics to advocate for specific treatment approaches among children and adolescents, is inadequate. Nicotine addiction and withdrawal have been linked to continued cigarette use and difficulty stopping. When adolescents first start smoking, few expect to have trouble quitting. However, more than half of smoking teens say they try to quit every year, and fewer than 20% of those who smoke ten or more cigarettes per day say they are successful for even a month. Treatment of tobacco addiction rely mainly on the behavioral interventions as medications safety are not assessed for those less than 18 years old, so more research should be encouraged to find about the safety and availability for alternatives as behavioral intervention is not suitable alone for moderate to severe cases, Tobacco products are used by youth in a variety of ways,When smoking cessation efforts are undertaken in developed and developing nations, the wide diversity of tobacco products must be taken into consideration. This research deals with the causes of tobacco dependence among young people, diagnosis and treatment methods.

Assessment of Tobacco Dependence in Al-Bayda City, Libya

Tobacco is the second leading cause of the death in adults in the world today. This is because of tobacco dependence. Therefore, aim of this study is to assess the level of nicotine dependence through a small random group of smokers in the city of Al-Bayda using the Fagerstrom test for nicotine dependence and to know the extent of desire to quit and take action. The study included 150 male smokers, with an age group ranging between 18-60 years, in the period between February and June 2020 through a questionnaire containing six questions from the Fagerstrom test and collected smoking risks and presence of smoking cessation medications. Data were collected and statistically evaluated using chi-square. Most of the participants had a family history, they were smoking imitating brother, father and friends. The average number of cigarettes consumed was more than 31 cigarettes per day, with a 5-minute time difference being the highest. The rate of desire to smoke was observed in the morning hours more than others. The proportion was also high for those who were unable to stop in public even while ill. Most of them are aware of the existence of drugs that help in smoking cessation. As for the attempts to quit, there were attempts during different periods of time, most of which failed due to physical and social reasons. Most of the results indicate a high rate of dependence among smokers, for reasons that may be social and economic. Therefore, we need more data and a wider study area through health centers and try to understand the reasons for returning to smoking and treating them. work to validate reliability.

Prevalence of tobacco dependence and associated factors among patients with schizophrenia attending their treatments at southwest Ethiopia; hospital-based cross-sectional study

Background Tobacco smoking is the most typically employed in patients with mental disorders; among them, patients with schizophrenia are the very best users. The rate of smoking among patients with schizophrenia is between two and three times greater than the general population in western countries. However, there is a scarcity of studies on the magnitude and associated factors of tobacco dependence among patients with schizophrenia in Ethiopia. Therefore, we assessed the prevalence of tobacco dependence and associated factors among patients with schizophrenia at Mettu Karl referral, Bedelle, and Agaro hospitals, Southwest, Ethiopia. Method Hospital-based the multistage stratified cross-sectional study design was conducted among 524 patients with schizophrenia who are on treatment. Fagerstrom Test for Nicotine Dependence (FTND) was used to screen the prevalence of tobacco dependence. Analysis of data was done using SPSS version 24. Result The prevalence of tobacco dependence among study participants was 22.3% (95% CI) (18.6, 26). Concerning the severity of tobacco dependence, 3.5%, 13.8%, and 5% of the respondents report moderate, high, and very high levels of tobacco dependence respectively. The proportions of tobacco dependence among male schizophrenic patients 88 (25.8%) were higher compared to their counterparts 27 (15.5%). After controlling the effects of cofounders in the final regression analysis, male gender (AOR 2.19, 95% CI = 1.25, 3.83), being on treatment for more than 5years (AOR 4.37, 95% CI = 2.11, 9.02), having a history of admission (AOR 4.01, 95% CI = 1.99, 8.11), and family history of mental illness (AOR 1.90, 95% CI = 1.04, 3.48) were shown to have a significant positive association with tobacco dependence. Conclusion and recommendation A study show a significant proportion of tobacco dependence among people living with schizophrenia. Factors like, being male gender, being on treatment for more than 5 years, having a history of admission, and family history of mental illness was found to have a significant positive association with tobacco dependence. Hence, there is a need for coordinated and comprehensive management clinically to manage tobacco dependence along with identified risk factors in patients with schizophrenia. Also the finding call for the clinicians, managers, ministry of health and other stakeholders on the substance use prevention strategies that target personal and environmental control.

Prevention of nicotine addiction at the enterprises of the Siberian Coal Energy Company

The problem of Smoking is widespread among different age groups of the population both in individual countries and in the world as a whole. According to official statistics, the number of regular tobacco users in the world reaches a billion. The harm of tobacco is caused by the content of toxic substances in the inhaled smoke, which have a negative impact on organs and systems, leading to the emergence of diseases or exacerbation of existing ones. Deaths due to diseases associated with tobacco use are not uncommon. Given the high mortality and morbidity from nosological forms, the risk of which is Smoking, prevention and methods of combating addiction are an important topic in modern medicine. This article presents the experience of using the auditory psycho-correction program “NO SMOKE” in the fight against tobacco dependence among employees of the coal Company.

Evidence of individual differences in motives for nicotine seeking in classical nicotine self-administration and associated outcomes of varenicline administration

Background Smokers vary in their motives for tobacco seeking, suggesting that they could benefit from personalized treatments. However, these variations have received little attention in animal models for the study of tobacco dependence. In the most classically used model, ie. intravenous self-administration of nicotine in the rat, seeking behaviour is reinforced by the combination of intravenous nicotine with a discrete stimulus (eg. discrete cue light). In both human and animals, two types of psychopharmacological interactions between nicotine and environmental stimuli have been evidenced. Whether these two types of interactions contribute equally to nicotine seeking in all individuals is unknown. Methods We combined behavioural pharmacology and clustering analysis. In an outbred male rat population, we tested whether nicotine and the discrete nicotine-associated cue light contributed equally to self-administration in all individuals. Two clusters of rats were identified, in which we further studied the nature of the psychopharmacological interaction between nicotine and the cue, as well as the response to the cessation aid varenicline when nicotine was withdrawn. Results Notably, withdrawing nicotine produced drastic opposed effects on seeking behavior in the two identified clusters of rats; a 50% increase vs a 18% decrease, respectively. The first cluster of rats sought for the primary reinforcing effects of nicotine and the discrete cue light that has gained nicotine-like secondary reinforcing properties. The second cluster sought nicotine for its ability to enhance the primary reinforcing effects of the discrete cue light. Critically, the approved cessation aid Varenicline counteracted the absence of nicotine in both, but eventually decreasing seeking in the former but increasing it in the latter. Conclusions Classical rodent models for the study of the reinforcing and addictive effects of nicotine hide individual variations in the psychopharmacological motives supporting seeking behavior. These variations may be a decisive asset for improving their predictive validity in the perspective of precision medicine for smoking cessation.